Clinical Diagnosis of COVID-19: A Prompt, Feasible, and Sensitive Diagnostic Tool Based on a 1,757-Patient Cohort (The AndroCoV Clinical Scoring for COVID-19 Diagnosis)

The study "Clinical diagnosis of COVID-19: a prompt, feasible, and sensitive diagnostic tool for COVID-19 based on a 1,757-patient cohort (The AndroCoV Clinical Scoring for COVID-19 diagnosis)" proposes a clinical scoring system for diagnosing COVID-19. The system was validated in a sample of 1,757 patients and is based on the number of symptoms, presence of anosmia, and known positive household contact. The study found that requiring two or more symptoms with or without anosmia or ageusia for subjects without known contact and one or more symptoms with or without anosmia or ageusia with known positive contacts presented the highest accuracy (80.4%). This method was found to be more accurate than most commercially available rtPCR-SARS-CoV-2 tests. The study concludes that this clinical scoring system is a feasible, quick, inexpensive, and sensitive diagnostic tool for clinical diagnosis of COVID-19, and should be recommended as a first-line option for COVID-19 diagnosis.